Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
November 17, 2020 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity...
Myovant Sciences Announces Corporate Updates and Financial Results for Second Quarter Fiscal Year 2020
November 12, 2020 07:00 ET
|
Myovant Sciences, Inc.
FDA Priority Review of New Drug Application (NDA) for relugolix monotherapy tablet for advanced prostate cancer on track for decision by December 20, 2020 target action dateNDA for relugolix...
Myovant Sciences to Host Second Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on November 12, 2020
November 02, 2020 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and...
Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine Fibroids
October 21, 2020 08:30 ET
|
Myovant Sciences, Inc.
Seven oral and poster presentations presented at the American Society for Reproductive Medicine (ASRM) 2020 Virtual CongressOral presentation on efficacy and safety data from Phase 3 SPIRIT program...
Myovant Sciences Appoints Ryan Crowe as Vice President, Investor Relations
October 14, 2020 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Ryan...
Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer
September 29, 2020 08:30 ET
|
Myovant Sciences, Inc.
Relugolix had a similar rate of castration resistance-free survival in the subgroup of men with metastatic disease compared to leuprolide acetate (74% vs. 75%, respectively) and did not achieve...
Myovant Sciences Launches “Forward for Health Equity” Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids
September 23, 2020 08:30 ET
|
Myovant Sciences, Inc.
Prostate cancer and uterine fibroids disproportionately impact Black Americans; racial disparities are exacerbated by inequities in healthcare access and COVID-19 pandemicMyovant expands ongoing...
Myovant Sciences Presents Additional Data on Bone Mineral Density in Women with Uterine Fibroids from Phase 3 LIBERTY Program and from Prospective Observational Study
September 14, 2020 08:30 ET
|
Myovant Sciences, Inc.
Relugolix combination therapy maintained bone mineral density through one year, consistent with bone mineral density changes observed in untreated womenFindings presented at the American Society for...
Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids
August 17, 2020 08:30 ET
|
Myovant Sciences, Inc.
FDA sets target action date of June 1, 2021 BASEL, Switzerland, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for...
Myovant Sciences Announces Corporate Updates and Financial Results for First Quarter Fiscal Year 2020
August 11, 2020 08:30 ET
|
Myovant Sciences, Inc.
New Drug Application (NDA) for relugolix monotherapy tablet in advanced prostate cancer accepted for Priority Review by the FDA with target action date of December 20, 2020NDA for relugolix...